论文部分内容阅读
目的 观察肺表面活性物质 (PS)对降低早产儿肺透明膜病 (HMD)呼吸机治疗条件的临床效果。方法 对 19例生后 4～ 8h患Ⅱ～Ⅲ级HMD的早产儿在机械通气治疗的基础上 ,给予气管内注入PS ,并与同期单纯用呼吸机治疗的 2 2例HMD作对照。观察 2组患儿的呼吸机条件及预后。结果 PS(治疗 )组高吸气峰压时间、高平均气道压时间、高吸氧浓度时间、上机时间 ,较对照组明显缩短 ,并发症中肺炎也较对照组明显减少 ,差异均有极显著意义。结论 PS治疗早产儿HMD可明显降低呼吸机治疗条件并改善预后。
Objective To observe the clinical effect of pulmonary surfactant (PS) on reducing the treatment of pulmonary hyaline membrane disease (HMD) in preterm infants. Methods Nineteen preterm infants with grade Ⅱ ~ Ⅲ HMD after 4 ~ 8h after birth were given PS intratracheal instillation and were compared with 22 cases of HMD treated with ventilator alone in the same period. The ventilator conditions and prognosis of two groups were observed. Results In PS group, the duration of high inspiratory pressure, high mean airway pressure, high oxygen concentration and time on the machine were significantly shorter than those in the control group, and pneumonia in complications was significantly lower than that in the control group Very significant. Conclusion PS treatment of preterm infant HMD can significantly reduce ventilator treatment conditions and improve prognosis.